Avalo Therapeutics (NASDAQ:AVTX) Rating Increased to Strong-Buy at Wedbush

Wedbush upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.

Several other equities research analysts also recently weighed in on AVTX. BTIG Research assumed coverage on Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target on the stock. HC Wainwright assumed coverage on Avalo Therapeutics in a report on Thursday, October 24th. They issued a “neutral” rating on the stock.

Avalo Therapeutics Stock Up 17.9 %

NASDAQ:AVTX opened at $8.44 on Thursday. Avalo Therapeutics has a 1 year low of $4.20 and a 1 year high of $34.46. The business has a 50 day simple moving average of $7.82 and a 200-day simple moving average of $9.40.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP purchased a new position in Avalo Therapeutics during the 4th quarter worth $114,000. Walleye Capital LLC purchased a new position in Avalo Therapeutics during the 4th quarter worth $145,000. Northern Trust Corp purchased a new position in Avalo Therapeutics during the 4th quarter worth $168,000. Finally, Bank of Montreal Can purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at $446,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.